<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33311560</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>02</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1759-507X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>17</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Nature reviews. Nephrology</Title>
          <ISOAbbreviation>Nat Rev Nephrol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Advances in ANCA-associated vasculitis and lupus nephritis.</ArticleTitle>
        <Pagination>
          <StartPage>89</StartPage>
          <EndPage>90</EndPage>
          <MedlinePgn>89-90</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41581-020-00388-x</ELocationID>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Ayoub</LastName>
            <ForeName>Isabelle</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Nephrology, The Ohio State University Wexner Medical Center, Columbus, OH, USA. isabelle.ayoub@osumc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nachman</LastName>
            <ForeName>Patrick H</ForeName>
            <Initials>PH</Initials>
            <Identifier Source="ORCID">0000-0002-5890-2862</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, MN, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03949855</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>England</Country>
        <MedlineTA>Nat Rev Nephrol</MedlineTA>
        <NlmUniqueID>101500081</NlmUniqueID>
        <ISSNLinking>1759-5061</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D056648" MajorTopicYN="N">Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="N">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>14</Day>
          <Hour>10</Hour>
          <Minute>49</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33311560</ArticleId>
        <ArticleId IdType="doi">10.1038/s41581-020-00388-x</ArticleId>
        <ArticleId IdType="pii">10.1038/s41581-020-00388-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Walsh, M., Merkel, P. A. &amp; Peh, C. A. et al. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N. Engl. J. Med. 382, 622–631 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1803537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith, R. M., Jones, R. B. &amp; Specks, U. et al. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann. Rheum. Dis. 79, 1243–1249 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/annrheumdis-2019-216863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone, J. H., Merkel, P. A. &amp; Spiera, R. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0909905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonelou, M., Michaelsson, E. &amp; Evans, R. D. R. et al. Therapeutic myeloperoxidase inhibition attenuates neutrophil activation, ANCA-mediated endothelial damage, and crescentic GN. J. Am. Soc. Nephrol. 31, 350–364 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2019060618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furie, R., Rovin, B. H. &amp; Houssiau, F. et al. Two-Year, randomized, controlled trial of belimumab in lupus nephritis. N. Engl. J. Med. 383, 1117–1128 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2001180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson, S. W. &amp; Davidson, A. BAFF inhibition in SLE-Is tolerance restored? Immunol. Rev. 292, 102–119 (2019).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/imr.12810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Atisha-Fregoso, Y., Malkiel, S. &amp; Harris, K. M. et al. CALIBRATE: a phase 2 randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis. Arthritis &amp; Rheumatology https://doi.org/10.1002/art.41466 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.41466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nickerson, K. M., Wang, Y., Bastacky, S. &amp; Shlomchik, M. J. Toll-like receptor 9 suppresses lupus disease in Fas-sufficient MRL Mice. PLoS One. 12, e0173471 (2017).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0173471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tilstra, J. S., John, S. &amp; Gordon, R. A. et al. B cell-intrinsic TLR9 expression is protective in murine lupus. J. Clin. Invest. 130, 3172–3187 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI132328</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
